FDA approves Roche’s Tecentriq Hybreza for cancer

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer immunotherapy.

The treatment offers a quicker and more comfortable administration option compared to the standard intravenous infusion.